scholarly journals Clearance of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection or Liver Transplantation

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2476
Author(s):  
Víctor Amado ◽  
Sandra González-Rubio ◽  
Javier Zamora ◽  
Rafael Alejandre ◽  
María Lola Espejo-Cruz ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Surgical Resection ◽  
Tumor Recurrence ◽  
Surrogate Marker ◽  
Blood Samples ◽  
Prospective Pilot Study

Background: In patients with hepatocellular carcinoma (HCC), a complete clearance of circulating tumor cells (CTCs) early after liver transplantation (LT) or surgical resection (LR) could prevent tumor recurrence. Methods: prospective pilot study including patients with HCC who underwent LR or LT from September 2017 to May 2020. Enumeration of CTCs was performed in peripheral blood samples (7 mL) using the Isoflux® system (Fluxion Biosciences) immediately before surgery, at post-operative day 5 and at day 30. A clinically relevant number of CTCs was defined as >30 CTCs/sample. Results: 41 HCC patients were included (mean age 58.7 ± 6.3; 82.9% male). LR was performed in 10 patients (24.4%) and 31 patients (75.6%) underwent LT. The main etiology of liver disease was chronic hepatitis C (31.7%). Patients undergoing LR and LT were similar in terms of preoperative CTC count (p = 0.99), but clearance of CTCs within the first month was more pronounced in the LT group. Clusters of CTCs at baseline were associated with incomplete clearance of CTCs at day 30 (54.2% vs. 11.8%, p = 0.005), which in turn impacted negatively on survival (p = 0.038). Conclusion: Incomplete clearance of CTCs after surgery could be a surrogate marker of HCC aggressiveness.

Postoperative detection of circulating EGFR transcripts as a surrogate marker for circulating tumor cells to predict tumor recurrence after adjuvant radio(chemo)therapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6014-6014 ◽  
Author(s):  
Inge Tinhofer ◽  
Robert Konschak ◽  
Carmen Stromberger ◽  
Ulrich Keilholz ◽  
Volker Budach
Keyword(s):  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Adjuvant Treatment ◽  
Tumor Recurrence ◽  
Locally Advanced ◽  
Surrogate Marker ◽  
Smoking History ◽  
Blood Samples ◽  
Cox Regression Analysis ◽  
N Stage

6014 Background: The prognostic role of circulating tumor cells (CTCs), occurring in up to 35% of LASCCHN patients, is still largely undetermined. In this prospective study we tested whether the detection of CTCs was associated with treatment outcome of adjuvant radio(chemo)therapy. Methods: Patients with LASCCHN (N=64) of the oropharynx (N=40), oral cavity (N=15), hypopharynx (N=3) or CUP (N=6) presenting after tumor surgery for adjuvant treatment were enrolled in this study. Peripheral blood samples were collected before start and at the end of adjuvant radio- (N=22) or radiochemotherapy (N=42). Transcripts of epidermal growth factor receptor (EGFR) were detected using RT-PCR. Samples positive in at least 2 of 3 PCR replicates were considered CTC-positive, according to previous studies. CTC detection was correlated with failure-free (FFS) and overall survival (OS). Results: CTCs were detected in blood samples from 21 of 64 patients (33%) whereas all 30 samples from healthy donors used as control were negative. The CTC+ and CTC- patient cohorts were comparable with relation to sex, age, smoking history, T and N stage, tumor localization, type of adjuvant treatment and the median follow-up for OS and FFS. Detection of CTCs before or after adjuvant treatment was not predictive for OS. However, the presence of CTCs at the start of adjuvant radio(chemo)therapy identified patients with reduced FFS (CTC- vs CTC+ [% of patients without relapse at 2 years]: 89% vs. 60%, HR: 0.30, 95% CI: .08-.92, p=.037). Multivariate Cox regression analysis revealed that the prognostic value of the CTC status was not influenced by the T and N stage and independent of whether the adjuvant treatment consisted of radio- or radiochemotherapy. Conclusions: Persistence of CTCs after tumor resection as detected by EGFR transcripts was established as an independent marker for tumor recurrence in LASCCHN. Postoperative detection of CTCs might prove useful for risk stratification in future clinical trials for optimization of adjuvant treatment, especially for the poor-prognosis group of CTC+ patients.

scholarly journals Analysis of preoperative circulating tumor cells for recurrence in patients with hepatocellular carcinoma after liver transplantation

2020 ◽  
Vol 8 (17) ◽  
pp. 1067-1067
Author(s):  
Zhitao Chen ◽  
Xiaohong Lin ◽  
Chuanbao Chen ◽  
Yinghua Chen ◽  
Qiang Zhao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Tumor Cells ◽  
Circulating Tumor Cells

scholarly journals Oncological Evaluation Using Circulating Tumor Cells and PET-CT of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S949-S950
Author(s):  
D. Ferreras ◽  
P. Cascales-Campos ◽  
F. Alconchel-Gago ◽  
F. Villalba-López ◽  
L.F. Saenz-Mateos ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Pet Ct

Preoperative detection of circulating tumor cells in patients with colorectal carcinoma: Correlation with clinicopathologic variables and recurrence.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 10578-10578
Author(s):  
Hideyasu Sakihama ◽  
Nozomi Kobayashi ◽  
Tohru Funakoshi ◽  
Tatsushi Shimokuni ◽  
Shigenori Homma ◽  
...  
Keyword(s):  
Healthy Volunteers ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Peripheral Blood ◽  
Tumor Recurrence ◽  
Strong Predictor ◽  
Depth Of Invasion ◽  
Blood Samples ◽  
Positive Rate ◽  
Colorectal Cancer Patients

10578 Background: The role of circulating tumor cells (CTC) in the management of colorectal cancer patients has not fully established. The aims of this study are to investigate the relationship between the presence of CTC with clinicopathological variables and recurrence by magnetic activated cell sorting (MACS) system. Methods: Peripheral blood samples were collected from 80 patients. Enrichment of CTC was performed by direct immunomagnetic labeling of EpCAM positive cells in peripheral blood. Subsequently, double immunofluorescence for cytokeratin and CD45 was performed to detect CTC. Peripheral blood samples from twenty healthy volunteers were used as controls. Results: Preoperative positive rate of CTC was 35% while specificity was 100%. No CTC was found in peripheral blood from healthy volunteers. No correlation was found between the presence of CTC and location of tumors, grade of differentiation, vessel invasion, lymph node metastasis or TNM stages. On the other hand, the depth of invasion (0% in Tis, 11.1% in T1, 18.2% in T2 and 34.7% in T3+T4, P=0.05) and tumor recurrence (28.2% for initial operation and 88.9% for reoperative surgery for tumor recurrence, P<0.001) closely correlated with the presence of CTC. Preoperative positive rate of CTC among patients who have recurred postoperatively was 75%. Conclusions: Our results indicate that detections of CTCs correlate with the depth of invasion and tumor recurrence. Preoperative presence of CTCs might be a strong predictor for tumor recurrence.

Analysis of circulating tumor cells in patients with hepatocellular carcinoma recurrence following liver transplantation

2018 ◽  
Vol 66 (5) ◽  
pp. 1.6-6 ◽  
Author(s):  
Shaoping Wang ◽  
Yujian Zheng ◽  
Jun Liu ◽  
Feng Huo ◽  
Jie Zhou
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Tumor Diameter ◽  
Multicenter Studies ◽  
Patients With Cancer ◽  
T Stage ◽  
Hepatocellular Carcinoma Recurrence ◽  
Hcc Recurrence

Although studies have shown that detection of peripheral circulating tumor cells (CTCs) is an important tool for monitoring prognosis and therapeutic response in patients with cancer, few studies have analyzed their role in patients with hepatocellular carcinoma (HCC) following liver transplantation (LTx). The present study examined whether CTC levels were associated with HCC recurrence in patients with HCC after LTx. This prospective study included 47 patients who received LTx between October 2014 and May 2016 and who underwent analysis for peripheral CTCs at least twice using the CanPatrol system. Baseline Edmondson stage, T stage, accumulated tumor diameter, microvascular cancer embolus, and alpha-fetoprotein (AFP) levels were greater in patients with recurrence (all p<0.05). In addition, 70.2% of patients with HCC were CTC-positive. Although the proportion of CTC subtypes changes following LTx and over the follow-up period with increased epithelial and interstitial CTC levels, no significant associations were observed between change in total CTCs or CTC subtype and HCC recurrence (all p>0.05). In conclusion, baseline Edmondson stage, T stage, accumulated tumor diameter, microvascular cancer embolus, and AFP levels may be predictive of HCC recurrence following LTx; however, CTC levels and subtypes were not. Further large, multicenter studies are necessary to confirm these results.

Sign in / Sign up

Export Citation Format

Share Document